- Home
- COP vs SNY Comparison
COP vs SNY Comparison
Compare COP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COP | SNY |
|---|---|---|
| Founded | 1917 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.5B | 104.5B |
| IPO Year | 2005 | 2001 |
Fundamental Metrics
Financial Performance| Metric | COP | SNY |
|---|---|---|
| Price | $130.58 | $45.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 5 |
| Target Price | ★ $123.65 | $58.00 |
| AVG Volume (30 Days) | ★ 6.0M | 3.0M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | 2.62% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.00 | N/A |
| Revenue | ★ $58,944,000,000.00 | N/A |
| Revenue This Year | $6.88 | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | $25.58 | ★ $6.14 |
| Revenue Growth | ★ 7.67 | N/A |
| 52 Week Low | $85.59 | $40.89 |
| 52 Week High | $135.87 | $52.68 |
Technical Indicators
Market Signals| Indicator | COP | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 69.98 | 66.69 |
| Support Level | $113.24 | $45.71 |
| Resistance Level | $135.87 | $48.66 |
| Average True Range (ATR) | 3.06 | 0.55 |
| MACD | 0.87 | 0.22 |
| Stochastic Oscillator | 91.48 | 92.94 |
Price Performance
Historical ComparisonAbout COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.